CO7061079A2 - Inhibidores de cinasa de fosfoinositida 3 cristalina - Google Patents
Inhibidores de cinasa de fosfoinositida 3 cristalinaInfo
- Publication number
- CO7061079A2 CO7061079A2 CO14190112A CO14190112A CO7061079A2 CO 7061079 A2 CO7061079 A2 CO 7061079A2 CO 14190112 A CO14190112 A CO 14190112A CO 14190112 A CO14190112 A CO 14190112A CO 7061079 A2 CO7061079 A2 CO 7061079A2
- Authority
- CO
- Colombia
- Prior art keywords
- phosphoinositide
- crystalline
- kinase inhibitors
- solid crystalline
- inamide
- Prior art date
Links
- 239000002935 phosphatidylinositol 3 kinase inhibitor Substances 0.000 title 1
- 229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 title 1
- 239000007787 solid Substances 0.000 abstract 3
- -1 (4-amino-3- (3-hydroxyphenyl) -1 H -pyrazolo [3,4-d] pyrimidin-1-yl) methyl Chemical group 0.000 abstract 1
- 125000006282 2-chlorobenzyl group Chemical group [H]C1=C([H])C(Cl)=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000000843 powder Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Otolaryngology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261610023P | 2012-03-13 | 2012-03-13 | |
| US201261610012P | 2012-03-13 | 2012-03-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO7061079A2 true CO7061079A2 (es) | 2014-09-19 |
Family
ID=49160309
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO14190112A CO7061079A2 (es) | 2012-03-13 | 2014-08-29 | Inhibidores de cinasa de fosfoinositida 3 cristalina |
| CO14190111A CO7051030A2 (es) | 2012-03-13 | 2014-08-29 | Formulaciones farmacéuticas novedosas |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO14190111A CO7051030A2 (es) | 2012-03-13 | 2014-08-29 | Formulaciones farmacéuticas novedosas |
Country Status (35)
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0918249D0 (en) | 2009-10-19 | 2009-12-02 | Respivert Ltd | Compounds |
| UY33337A (es) | 2010-10-18 | 2011-10-31 | Respivert Ltd | DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS |
| UA115544C2 (uk) | 2012-03-13 | 2017-11-27 | Респіверт Лімітед | Спосіб підвищення стабільності до хімічного розкладання фармацевтичної композиції та застосування стабілізуючого агента у фармацевтичній коипозиції |
| US8940742B2 (en) | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| WO2014072937A1 (en) | 2012-11-08 | 2014-05-15 | Rhizen Pharmaceuticals Sa | Pharmaceutical compositions containing a pde4 inhibitor and a pi3 delta or dual pi3 delta-gamma kinase inhibitor |
| TW201522341A (zh) | 2013-03-15 | 2015-06-16 | Respivert Ltd | 化合物 |
| US9227977B2 (en) | 2013-03-15 | 2016-01-05 | Respivert Ltd. | Phosphoinositide 3-kinase inhibitors |
| PT3052485T (pt) | 2013-10-04 | 2021-10-22 | Infinity Pharmaceuticals Inc | Compostos heterocíclicos e suas utilizações |
| US9751888B2 (en) | 2013-10-04 | 2017-09-05 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| MX382033B (es) | 2014-03-19 | 2025-03-13 | Infinity Pharmaceuticals Inc | Compuestos heterocíclicos para utilizarlos en el tratamiento de trastornos mediados por pi3k-gamma. |
| HK1232227A1 (zh) | 2014-07-04 | 2018-01-05 | Lupin Limited | 作为pi3k抑制剂的喹嗪酮衍生物 |
| EA201692456A1 (ru) * | 2014-07-09 | 2017-08-31 | Арвен Иладж Санайи Ве Тиджарет А.Ш. | Способ получения составов для ингаляции |
| WO2016054491A1 (en) | 2014-10-03 | 2016-04-07 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| WO2017048702A1 (en) | 2015-09-14 | 2017-03-23 | Infinity Pharmaceuticals, Inc. | Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same |
| WO2017161116A1 (en) | 2016-03-17 | 2017-09-21 | Infinity Pharmaceuticals, Inc. | Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors |
| SG11201809042SA (en) | 2016-04-15 | 2018-11-29 | Chia Tai Tianqing Pharmaceutical Group Co Ltd | Inhaled preparation of isoglycyrrhizic acid or salt thereof, and use in preparing drugs for treating respiratory system diseases |
| WO2017214269A1 (en) | 2016-06-08 | 2017-12-14 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
Family Cites Families (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1204826B (it) | 1986-03-04 | 1989-03-10 | Chiesi Farma Spa | Composizioni farmaceutiche per inalazione |
| GB9501841D0 (en) | 1995-01-31 | 1995-03-22 | Co Ordinated Drug Dev | Improvements in and relating to carrier particles for use in dry powder inhalers |
| WO1999028979A2 (en) | 1997-12-02 | 1999-06-10 | Alcatel Usa Sourcing, L.P. | Digital phone system |
| PL200941B1 (pl) | 1998-11-13 | 2009-02-27 | Jagotec Ag | Suchy proszkowy preparat inhalacyjny |
| US6383790B1 (en) | 1999-01-11 | 2002-05-07 | Princeton University | High affinity protein kinase inhibitors |
| ATE363892T1 (de) | 1999-03-05 | 2007-06-15 | Chiesi Farma Spa | Verbesserte pulverformulierungen zur inhalation |
| PE20011227A1 (es) | 2000-04-17 | 2002-01-07 | Chiesi Farma Spa | Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros |
| US6667300B2 (en) | 2000-04-25 | 2003-12-23 | Icos Corporation | Inhibitors of human phosphatidylinositol 3-kinase delta |
| US6608053B2 (en) | 2000-04-27 | 2003-08-19 | Yamanouchi Pharmaceutical Co., Ltd. | Fused heteroaryl derivatives |
| KR100774855B1 (ko) | 2000-04-27 | 2007-11-08 | 아스텔라스세이야쿠 가부시키가이샤 | 축합 헤테로아릴 유도체 |
| EP1217000A1 (en) | 2000-12-23 | 2002-06-26 | Aventis Pharma Deutschland GmbH | Inhibitors of factor Xa and factor VIIa |
| WO2003006628A2 (en) | 2001-07-13 | 2003-01-23 | Virtual Drug Development, Inc. | Nad synthetase inhibitors and uses thereof |
| AU2002317377A1 (en) | 2001-07-20 | 2003-03-03 | Cancer Research Technology Limited | Biphenyl apurinic/apyrimidinic site endonuclease inhibitors to treat cancer |
| WO2004037176A2 (en) | 2002-10-21 | 2004-05-06 | Bristol-Myers Squibb Company | Quinazolinones and derivatives thereof as factor xa inhibitors |
| RU2366655C2 (ru) | 2003-03-14 | 2009-09-10 | Оно Фармасьютикал Ко., Лтд. | Азотсодержащие гетероциклические производные и лекарственные средства, содержащие их в качестве активного ингредиента |
| US7122557B2 (en) | 2003-03-18 | 2006-10-17 | Bristol-Myers Squibb Company | Sulfonyl-amidino-containing and tetrahydropyrimidino-containing compounds as factor Xa inhibitors |
| JP2007524605A (ja) | 2003-04-03 | 2007-08-30 | ピーディーエル バイオファーマ，インコーポレイティド | インテグリンα５β１のインヒビターおよび組織顆粒化の制御のためのそれらの使用 |
| US7429596B2 (en) | 2003-06-20 | 2008-09-30 | The Regents Of The University Of California | 1H-pyrrolo [2,3-D] pyrimidine derivatives and methods of use thereof |
| GB0316341D0 (en) * | 2003-07-11 | 2003-08-13 | Glaxo Group Ltd | Pharmaceutical formulations |
| EP1643973A1 (en) | 2003-07-11 | 2006-04-12 | Glaxo Group Limited | Pharmaceutical formulations comprising magnesium stearate |
| JPWO2005012221A1 (ja) | 2003-08-04 | 2006-09-14 | 小野薬品工業株式会社 | ジフェニルエーテル化合物、その製造方法および用途 |
| US20050054614A1 (en) | 2003-08-14 | 2005-03-10 | Diacovo Thomas G. | Methods of inhibiting leukocyte accumulation |
| WO2005016348A1 (en) | 2003-08-14 | 2005-02-24 | Icos Corporation | Method of inhibiting immune responses stimulated by an endogenous factor |
| GB0326632D0 (en) | 2003-11-14 | 2003-12-17 | Jagotec Ag | Dry powder formulations |
| CA2552664A1 (en) | 2004-01-08 | 2005-07-28 | Michigan State University | Methods for treating and preventing hypertension and hypertension-related disorders |
| CA2566436C (en) | 2004-05-13 | 2011-05-10 | Vanderbilt University | Phosphoinositide 3-kinase delta selective inhibitors for inhibiting angiogenesis |
| WO2005113556A1 (en) * | 2004-05-13 | 2005-12-01 | Icos Corporation | Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta |
| WO2005117889A1 (en) | 2004-05-25 | 2005-12-15 | Icos Corporation | Methods for treating and/or preventing aberrant proliferation of hematopoietic |
| EP1750715A1 (en) | 2004-06-04 | 2007-02-14 | Icos Corporation | Methods for treating mast cell disorders |
| US8143404B2 (en) | 2004-09-13 | 2012-03-27 | Ono Pharmaceutical Co., Ltd | Nitrogenous heterocylic derivative and medicine containing the same as an active ingredient |
| GB0425758D0 (en) | 2004-11-23 | 2004-12-22 | Vectura Ltd | Preparation of pharmaceutical compositions |
| WO2006089106A2 (en) | 2005-02-17 | 2006-08-24 | Icos Corporation | Phosphoinositide 3-kinase inhibitors for inhibiting leukocyte accumulation |
| GB0525254D0 (en) | 2005-12-12 | 2006-01-18 | Jagotec Ag | Powder compositions for inhalation |
| SI2004654T1 (sl) | 2006-04-04 | 2013-11-29 | The Regents Of The University Of California | Pirazolopirimidinski derivati za uporabo kot kinazni antagonisti |
| WO2007114926A2 (en) | 2006-04-04 | 2007-10-11 | The Regents Of The University Of California | Kinase antagonists |
| EA200802348A1 (ru) | 2006-05-24 | 2009-08-28 | Байер Шеринг Фарма Акциенгезельшафт | ЧЕЛОВЕЧЕСКИЙ ВЫСОКОАФФИННЫЙ И ГУМАНИЗИРОВАННЫЙ АНТИ-α5β1 ИНТЕГРИН С ФУНКЦИЕЙ БЛОКИРУЮЩЕГО АНТИТЕЛА С ОСЛАБЛЕННОЙ ИММУНОГЕННОСТЬЮ |
| CA2655720A1 (en) | 2006-06-29 | 2008-01-10 | Schering Corporation | Substituted bicyclic and tricyclic thrombin receptor antagonists |
| GB0622818D0 (en) | 2006-11-15 | 2006-12-27 | Jagotec Ag | Improvements in or relating to organic compounds |
| CA2668744C (en) | 2006-11-17 | 2015-09-15 | Queen's University At Kingston | Compounds and methods for treating protein folding disorders |
| WO2008067219A2 (en) | 2006-11-29 | 2008-06-05 | Kalypsys, Inc. | Quinazolinone modulators of tgr5 |
| EP2137158A4 (en) | 2007-02-28 | 2012-04-18 | Methylgene Inc | LOW-MOLECULAR INHIBITORS OF PROTEINARGININE METHYLTRANSFERASES (PRMTS) |
| AR066477A1 (es) * | 2007-05-09 | 2009-08-19 | Novartis Ag | Imidazopiridazinas sustituidas como inhibidores de cinasa de lipido |
| WO2008140750A1 (en) | 2007-05-10 | 2008-11-20 | Hydra Biosciences Inc. | Compounds for modulating trpv3 function |
| MX2010007419A (es) | 2008-01-04 | 2010-11-12 | Intellikine Inc | Ciertas entidades quimicas, composiciones y metodos. |
| CA2738429C (en) | 2008-09-26 | 2016-10-25 | Intellikine, Inc. | Heterocyclic kinase inhibitors |
| WO2010059593A1 (en) | 2008-11-18 | 2010-05-27 | Intellikine, Inc. | Methods and compositions for treatment of ophthalmic conditions |
| WO2010065923A2 (en) | 2008-12-04 | 2010-06-10 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Phosphatidylinositol-3-kinase p110 delta-targeted drugs in the treatment of cns disorders |
| US8658648B2 (en) | 2008-12-05 | 2014-02-25 | Designmedix, Inc. | Modified chloroquines with single ring moiety or fused ring moiety |
| US20110135655A1 (en) | 2009-01-13 | 2011-06-09 | PHILADELPHIA HEALTH AND EDUCATION CORPORATION d/b/a Drexel University College of Medicine; | Role of PI3K p110 delta Signaling in Retroviral Infection and Replication |
| BRPI1012333A2 (pt) | 2009-03-24 | 2016-03-29 | Gilead Calistoga Llc | atropisômeros de derivados de 2-purinil-3-tolil-quinazolinonas e métodos de uso |
| SG178106A1 (en) | 2009-08-05 | 2012-03-29 | Versitech Ltd | Antiviral compounds and methods of making and using thereof |
| GB0918249D0 (en) | 2009-10-19 | 2009-12-02 | Respivert Ltd | Compounds |
| WO2011083387A1 (en) | 2010-01-07 | 2011-07-14 | Pfizer Limited | Hydrochloride salt of biphenyl-2-yl-carbamic acid 1-{9-[(3-fluoro-4-hydroxy-benzoyl)-methyl-amino]-nonyl}-piperidin-4-yl ester |
| CN201676365U (zh) | 2010-03-29 | 2010-12-22 | 山东京卫制药有限公司 | 带有语音提示的给药吸入装置 |
| CN201692450U (zh) | 2010-06-22 | 2011-01-05 | 于清 | 用于药物输送的高效干粉吸入器 |
| AU2011298315B2 (en) | 2010-08-31 | 2014-08-28 | Glaxo Group Limited | Dry powder inhalation drug products exhibiting moisture control properties and methods of administering the same |
| RU2580890C2 (ru) | 2010-09-30 | 2016-04-10 | КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. | Применение стеарата магния в составах сухого порошка для ингаляции |
| UY33337A (es) | 2010-10-18 | 2011-10-31 | Respivert Ltd | DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS |
| CN202154919U (zh) | 2011-05-03 | 2012-03-07 | 王晓明 | 一种防交叉感染雾化吸入装置 |
| UA115544C2 (uk) | 2012-03-13 | 2017-11-27 | Респіверт Лімітед | Спосіб підвищення стабільності до хімічного розкладання фармацевтичної композиції та застосування стабілізуючого агента у фармацевтичній коипозиції |
-
2013
- 2013-03-13 UA UAA201408662A patent/UA115544C2/uk unknown
- 2013-03-13 CN CN201380013848.1A patent/CN104284679B/zh not_active Expired - Fee Related
- 2013-03-13 TW TW102108767A patent/TWI617561B/zh not_active IP Right Cessation
- 2013-03-13 NZ NZ627963A patent/NZ627963A/en not_active IP Right Cessation
- 2013-03-13 CN CN201380013851.3A patent/CN104302650B/zh not_active Expired - Fee Related
- 2013-03-13 EA EA201491674A patent/EA025465B1/ru not_active IP Right Cessation
- 2013-03-13 EA EA201491675A patent/EA023715B1/ru not_active IP Right Cessation
- 2013-03-13 EP EP13711104.3A patent/EP2825202B1/en active Active
- 2013-03-13 LT LTEP13711105.0T patent/LT2834244T/lt unknown
- 2013-03-13 AU AU2013234081A patent/AU2013234081B2/en not_active Ceased
- 2013-03-13 KR KR1020147026305A patent/KR20140131971A/ko not_active Ceased
- 2013-03-13 NZ NZ628072A patent/NZ628072A/en not_active IP Right Cessation
- 2013-03-13 WO PCT/GB2013/050623 patent/WO2013136075A1/en not_active Ceased
- 2013-03-13 MX MX2014010990A patent/MX357170B/es active IP Right Grant
- 2013-03-13 JP JP2014561515A patent/JP2015509973A/ja active Pending
- 2013-03-13 US US14/381,273 patent/US20150099768A1/en not_active Abandoned
- 2013-03-13 DK DK13711105.0T patent/DK2834244T3/en active
- 2013-03-13 PE PE2014001414A patent/PE20141964A1/es not_active Application Discontinuation
- 2013-03-13 US US14/381,289 patent/US9642799B2/en not_active Expired - Fee Related
- 2013-03-13 CA CA 2864643 patent/CA2864643A1/en not_active Abandoned
- 2013-03-13 IN IN1998MUN2014 patent/IN2014MN01998A/en unknown
- 2013-03-13 HU HUE13711105A patent/HUE029420T2/en unknown
- 2013-03-13 PT PT137111050T patent/PT2834244T/pt unknown
- 2013-03-13 IN IN2000MUN2014 patent/IN2014MN02000A/en unknown
- 2013-03-13 WO PCT/GB2013/050624 patent/WO2013136076A1/en not_active Ceased
- 2013-03-13 ES ES13711105.0T patent/ES2600705T3/es active Active
- 2013-03-13 TW TW102108766A patent/TWI586378B/zh not_active IP Right Cessation
- 2013-03-13 HR HRP20161383TT patent/HRP20161383T1/hr unknown
- 2013-03-13 SI SI201330362A patent/SI2834244T1/sl unknown
- 2013-03-13 EP EP13711105.0A patent/EP2834244B1/en active Active
- 2013-03-13 JP JP2014561514A patent/JP6189874B2/ja not_active Expired - Fee Related
- 2013-03-13 MX MX2014010991A patent/MX355299B/es active IP Right Grant
- 2013-03-13 CA CA 2864652 patent/CA2864652A1/en not_active Abandoned
- 2013-03-13 AU AU2013234080A patent/AU2013234080B2/en not_active Ceased
- 2013-03-13 SG SG11201404522VA patent/SG11201404522VA/en unknown
- 2013-03-13 PE PE2014001415A patent/PE20142342A1/es not_active Application Discontinuation
- 2013-03-13 SG SG11201404519UA patent/SG11201404519UA/en unknown
- 2013-03-13 KR KR1020147026258A patent/KR20140141596A/ko not_active Ceased
- 2013-03-13 MY MYPI2014702576A patent/MY171125A/en unknown
- 2013-03-13 ES ES13711104.3T patent/ES2650791T3/es active Active
- 2013-03-13 PL PL13711105T patent/PL2834244T3/pl unknown
-
2014
- 2014-07-30 PH PH12014501713A patent/PH12014501713A1/en unknown
- 2014-07-30 IL IL233886A patent/IL233886A/en not_active IP Right Cessation
- 2014-07-30 IL IL233883A patent/IL233883A0/en unknown
- 2014-08-27 PH PH12014501922A patent/PH12014501922A1/en unknown
- 2014-08-29 CO CO14190112A patent/CO7061079A2/es unknown
- 2014-08-29 CO CO14190111A patent/CO7051030A2/es unknown
- 2014-09-01 GT GT201400182A patent/GT201400182A/es unknown
- 2014-09-02 GT GT201400183A patent/GT201400183A/es unknown
- 2014-09-05 NI NI201400101A patent/NI201400101A/es unknown
- 2014-09-05 NI NI201400100A patent/NI201400100A/es unknown
- 2014-09-09 CL CL2014002385A patent/CL2014002385A1/es unknown
- 2014-09-09 CL CL2014002386A patent/CL2014002386A1/es unknown
- 2014-09-10 CR CR20140417A patent/CR20140417A/es unknown
- 2014-09-10 CR CR20140416A patent/CR20140416A/es unknown
- 2014-09-10 EC ECIEPI201418142A patent/ECSP14018142A/es unknown
- 2014-09-12 EC ECIEPI201418630A patent/ECSP14018630A/es unknown
- 2014-10-10 ZA ZA2014/07374A patent/ZA201407374B/en unknown
- 2014-10-10 ZA ZA2014/07373A patent/ZA201407373B/en unknown
-
2016
- 2016-11-09 CY CY20161101148T patent/CY1118565T1/el unknown
-
2017
- 2017-05-08 US US15/588,845 patent/US20170239256A1/en not_active Abandoned
- 2017-08-04 JP JP2017151378A patent/JP2018008992A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO7061079A2 (es) | Inhibidores de cinasa de fosfoinositida 3 cristalina | |
| IL293621A (en) | Modified release formulations of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[4,3-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4 -Methyl-4-[4-(oxane-3-yl)piperazine-1-yl)penta-2-ananitrile | |
| IL272622A (en) | Use of proton tyrosine kinase inhibitors | |
| CR20140558A (es) | Formas cristalinas de un inhibidor de tirosina quinasa de bruton | |
| HUE061909T2 (hu) | Pirazolo[1,5-a]pirimidinek alkalmazása ATR kináz inhibítorként, rákos megbetegedések kezelésére | |
| GT201400196A (es) | Compuestos de heterociclilo | |
| PE20150637A1 (es) | Derivados de pirrolotriazinona como inhibidores de pi3k | |
| NZ702571A (en) | 4-(substituted-amino)-7h-pyrrolo[2,3-d]pyrimidines as lrrk2 inhibitors | |
| CL2013003051A1 (es) | Compuestos derivados de pirazolo (4.3-d) pirimidinas, inhibidores de quinasa; composicion farmaceutica; y uso para el tratamiento de enfermedades y trastornos del aparato respiratorio | |
| ZA201209381B (en) | The use of inhibitors of bruton's tyrosine kinase (btk) | |
| MX2012009074A (es) | Compuestos de urea pirrolo [2, 3-d] pirimidina como inhibidores de janus quinasa. | |
| CL2013001057A1 (es) | Un compuesto 6-(2-((4-amino-3-(3-hidroxifenil)-1h-pirazolo[3,4-d]pirimidin-1-il)metil)-3-(2-clorobencil)-4-oxo-3,4-dihidroquinazolin-5-il)-n,n-bis(2-metoxietil)hex-5-inamida, inhibidores de pi3 cinasa; compuesto intermediario; composicion farmaceutica, util para tratar o prevenir epoc, rinitis, artritis reumatoidea y carcinomas. | |
| CU20150078A7 (es) | Derivados de cicloalquilo pirrolo [2, 3-d]pirimidina -4-il amino útiles como inhibidores de quinasas janus relacionadas y composiciones farmacéuticas que contienen tales compuestos | |
| HUE029174T2 (hu) | Pirazolo[1,5-A]pirimidinek és -triazinok mint antivirális szerek | |
| MX2019005154A (es) | Derivados de [1,2,4]triazol[1,5-a]pirimidina como inhibidores de pde2. | |
| JO3279B1 (ar) | مشتقات 2-((4- امينو -3- (3- فلورو-5- هيدروكسي فينيل)-h1- بيرازولو [d-3,4] بيرمدين-1-يل )ميثيل )- 3- (2- تراي فلورو ميثيل ) بينزيل ) كوينازولين -4 (h3)- واحد واستخدامها كمثبطات فوسفواينوسيتايد 3- كاينيز | |
| BR112018071440A2 (pt) | comprimidos desintegráveis oralmente | |
| MX2019005123A (es) | Compuestos de [1,2,4]triazolo[1,5-a]pirimidina como inhibidores de pde2. | |
| TH156276A (th) | ตัวยับยั้ง pi3 ไคเนสที่เป็นผลึก | |
| EA201391630A1 (ru) | Новые противогрибковые 5,6-дигидро-4h-пирроло[1,2-a][1,4]бензодиазепины и 6h-пирроло[1,2-a][1,4]бензодиазепины, замещенные гетероциклическими производными |